Skip to main content

Table 2 Patients with different clinical conditions vaccinated with CIGB-247 and treated with different cancer therapies

From: Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Patient code

Diagnosis

Metastases

Relevant information

Immunogenicity/Safety profile

UC-CH47

Breast carcinoma

Lung

Cardiopathy patient that received CIGB-247 simultaneous with QT (Capecitabine and Letrozol).

Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on heart disease.

UC-CH77

Breast carcinoma

Bones

Patient that received CIGB-247 simultaneous with QT (Capecitabine, Zoledronic acid) and Trastuzumab

Patient positive for anti-VEGF antibody response.

UC-CH49

Ovary ADC

Peritoneum

Patient that received CIGB-247 simultaneous with QT (Docetaxel, Carboplatin)

Patient positive for anti-VEGF antibody response.

UC-HA03

Ovary ADC

Contralateral ovary

Patient that received CIGB-247 simultaneous with QT (Paclitaxel, Carboplatin) and G-CSF

Patient positive for anti-VEGF antibody response.

UC-HA07

Ovary ADC

Contralateral ovary

Patient that received CIGB-247 simultaneous with QT (Taxol, Cisplatin)

Patient positive for anti-VEGF antibody response.

UC-CQ108

Bladder ADC

Lung

Patient that received CIGB-247 simultaneous with QT (Gemcitabine, Carboplatin)

Patient positive for anti-VEGF antibody response.

UC-CH10

Hodgkin lymphoma

LN

Patient that received CIGB-247 simultaneous with QT (Procarbazine, Vincristine) and prednisone

Patient positive for anti-VEGF antibody response.

UC-CH11

SCLC

Neck, contralateral pulmonary metastases

Patient that received CIGB-247 simultaneous with QT (Cisplatin, Etoposide (VP-16), taxol, vincristine) and G-CSF.

Patient positive for anti-VEGF antibody response.

UC-CQ105

Rectum ADC

Vaccination with CIGB-247 was applied simultaneous with QT (Capecitabine)

Patient positive for anti-VEGF antibody response.

UC-HA01

Peritoneum carcinoma

Patient that received CIGB-247 simultaneous with QT (Docetaxel, Paclitaxel) and submitted to a major abdominal surgery (phlegmon).

Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on wound healing.

UC-CH22

Breast carcinoma

Contralateral breast and LN

After fifth vaccination with CIGB-247, patient was submitted to urgency surgery (right tubo-ovarian abscess) and immunization was not interrupted.

Patient positive for anti-VEGF antibody response a. Physician did not report any negative incidence on wound healing.

UC-HA14

Ovary ADC

Insulin-dependent diabetic patient with oral administration of metformin

Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on diabetes condition.

UC-CH48

Ovary carcinoma

Liver, brain, peritoneum

Patient diagnosed with diabetes mellitus

Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on diabetes condition.

UC-CH08

Malignant pleural mesothelioma

Cardiopathy patient with diabetes mellitus

Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on chronic diseases.

UC-CH38

Osteosarcoma

Lung

Patient with controlled-chronic bronchial asthma

Patient positive for anti-VEGF antibody response.

UC-CH25

Cervix carcinoma

Liver and bones

Patient diagnosed with systemic lupus erythematosus

Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on autoimmune disease.

UC-CH46

Thyroid carcinoma

LN and lung

Patient that received CIGB-247 simultaneous with oral levothyroxine

Patient positive for anti-VEGF antibody response.

UC-CQ116

RCC

Lung

Patient that received CIGB-247 simultaneous with recombinant IFN-α2b

Patient positive for anti-VEGF antibody response.

UC-CQ111

GBM

Patient that received CIGB-247 simultaneous with RT

Patient positive for anti-VEGF antibody response.

  1. aPatient positive for anti-VEGF antibody response is referred to subjects that showed at least one serum sample with antibodies specific to VEGF or with VEGF blocking activity detected during induction or re-immunization phases. ADC adenocarcinoma, QT chemotherapy, LN lymph nodes, RT radiotherapy, G-CSF granulocyte-colony stimulating factor, SCLC small cell lung cancer, GBM Glioblastoma multiforme, RCC Renal cell carcinoma, IFN Interferon